Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;7(2):99-102.
doi: 10.1177/1756283X13504728.

Immunoglobulin therapy for refractory Crohn's disease

Shailja Shah  1 , Jonathan Terdiman  2 , Katherine Gundling  3 , Uma Mahadevan  4
Affiliations

Immunoglobulin therapy for refractory Crohn's disease

Shailja Shah et al. Therap Adv Gastroenterol. 2014 Mar.
No abstract available

Keywords: Crohn’s disease; immunoglobulin; inflammatory bowel disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Before intravenous immunoglobulin (IVIg).
Figure 2.
Figure 2.
After intravenous immunoglobulin (IVIg).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abolhassani H., Sadaghiani M., Aghamohammadi A., Ochs H., Rezaei N. (2012) Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. J Clin Immunol 32: 1180–1192 - PubMed
    1. Berger M., Murphy E., Riley P., Bergman G. and VIRTUE Trial Investigators (2010) Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 103: 856–863 - PubMed
    1. Chapel H., Spickett G., Ericson D., Engl W., Eibl M., Bjorkander J. (2000) The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20: 94–100 - PubMed
    1. Danieli M., Pettinari L., Moretti R., Logullo F., Gabrielli A. (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10: 144–149 - PubMed
    1. Gardulf A. (2007) Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Biodrugs 21: 105–116 - PubMed

LinkOut - more resources